Latest Updates
-
Diwali 2026: Chakli To Nimki, 7 Regional Savoury Snacks That Bring Traditional Indian Flavours To Your Table -
Filmmaker Sanjay Gupta Passes Away At 57: ‘Aatish’ To ‘Kaabil’, Look At His Three-Decade Bollywood Journey -
Halloween 2026: From Chudail To Yakshi, 5 Mysterious Supernatural Beings That Haunt Indian Folklore -
Rashtriya Ekta Diwas 2026: Significance, History And Sardar Vallabhbhai Patel's Role In Uniting India -
Survey Finds 68% Of Previously Married Singles Hesitate To Match With Never-Married Partners -
Diwali 2026: Complete Five-Day Festival Calendar, Dates, Significance And Celebrations -
Weight, Alcohol, Hormones: Pathologist Shares Insights On What Really Shapes A Woman’s Breast Cancer Risk -
Diwali 2026: 5 Healthy Homemade Indian Sweets That Go Beyond Traditional Mithai -
Stroke In Young Women: Neurologist Explains Warning Signs And Hormonal Risk Factors -
‘Star Trek’ And ‘X-Men’ Actor Patrick Stewart Passes Away At 86 After Dementia Battle
Corbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
Allowing Biological E's Corbevax as a booster for those fully vaccinated against COVID-19 with either Covishield or Covaxin is likely to be considered by the NTAGI, which is scheduled to meet on Tuesday, sources said.

The Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. India's first indigenously-developed RBD protein subunit vaccine, Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
"The National Technical Advisory Group on Immunisation (NTAGI) will discuss allowing Corbevax, which has been cleared by the DCGI, as a booster for those fully vaccinated with Covishield or Covaxin," a source told PTI.
The government advisory panel is also expected to review the trial data of the country's first quadrivalent human papillomavirus (qHPV) vaccine against cervical cancer, developed by the Serum Institute of India.
A separate HPV working group of the NTAGI had, on June 8, examined the vaccine's clinical trial data and usefulness for inclusion in the national immunisation programme, sources had said.
The recommendation of the Standing Technical Sub-Committee (STSC) of the NTAGI on reducing the gap between the second dose and the precaution dose of Covid vaccines from nine to six months may also be ratified at the meeting to be chaired by the Union health secretary. PTI PLB RC
Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.



Click it and Unblock the Notifications
